Lineage Cell Therapeutics (LCTX) Asset Writedowns and Impairment (2010 - 2025)
Lineage Cell Therapeutics (LCTX) posted quarterly Asset Writedowns and Impairment of $14.8 million for Q2 2025, up 9900.0% quarter-over-quarter from $148000.0 in Q4 2016.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Asset Writedowns and Impairment (2010 - 2025) Analysis & Trends
Lineage Cell Therapeutics' Asset Writedowns and Impairment history runs 6 years deep, the most recent figure standing at $14.8 million for Q2 2025.
- In Q2 2025, Asset Writedowns and Impairment changed N/A year-over-year to $14.8 million; the TTM figure through Dec 2025 stood at $14.8 million (up 9900.0% YoY), while the FY2025 annual figure was $14.8 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q2 2025 stood at $14.8 million, up from $148000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $14.8 million in Q2 2025, with the low at $14.8 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 14.84 Mn |
| Dec 31, 2016 | 148,000.00 |
| Sep 30, 2016 | 448,000.00 |
| Dec 31, 2014 | -25,000.00 |
| Sep 30, 2014 | -12,000.00 |
| Jun 30, 2014 | 12,424.00 |
| Mar 31, 2014 | 8,576.00 |
| Dec 31, 2013 | 120.00 |
| Sep 30, 2013 | -5,830.00 |
| Jun 30, 2013 | -813.00 |
| Mar 31, 2013 | 1,523.00 |
| Dec 31, 2012 | 14,684.00 |
| Sep 30, 2012 | 1,451.00 |
| Jun 30, 2012 | 3,546.00 |
| Dec 31, 2011 | 98,720.00 |
| Jun 30, 2011 | -2,498.00 |
| Mar 31, 2011 | 4,008.00 |
| Dec 31, 2010 | 4,008.00 |